Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 10/20 | 0.60 |
| ▸ | PIM3 | Q86V86 | 10/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.56 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.48 |
| ▸ | NEK2 | P51955 | 1/20 | 0.48 |
| ▸ | STK3 | Q13188 | 1/20 | 0.48 |
| ▸ | CAMK4 | Q16566 | 1/20 | 0.48 |
| ▸ | TSSK2 | Q96PF2 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13156288 | 0.89 | PIM1 (0.57) | PIM1PIM3CHEK1PIM2BACE1 | |
| SCHEMBL13156380 | 0.88 | PIM1 (0.51) | PIM1PIM3CHEK1PIM2JAK2 | |
| SCHEMBL2849949 | 0.88 | PIM1 (0.55) | PIM1PIM3CHEK1PIM2JAK2 | |
| SCHEMBL13156857 | 0.88 | PIM1 (0.55) | PIM1PIM3CHEK1PIM2JAK2 | |
| SCHEMBL13156354 | 0.88 | CHEK1 (0.59) | PIM1PIM3CHEK1JAK2ROCK2 | |
| SCHEMBL12550556 | 0.87 | PIM1 (0.55) | PIM1PIM3CHEK1PIM2JAK2 | |
| SCHEMBL14216463 | 0.87 | PIM1 (0.55) | PIM1PIM3CHEK1PIM2JAK2 | |
| SCHEMBL13156858 | 0.87 | CHEK1 (0.49) | PIM1PIM3CHEK1PIM2JAK2 | |
| SCHEMBL13156356 | 0.85 | CHEK1 (0.53) | PIM1PIM3CHEK1PIM2JAK2 | |
| SCHEMBL13156304 | 0.85 | CHEK1 (0.49) | PIM1PIM3CHEK1PIM2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318735-B2 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-05-27 | — | — | US | disclosed |
| WO-2008054749-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | PIM1 644/4885PIM3 811/4885CHEK1 61/4885 |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MAPK15, CDK15, MAP3K15 | PIM1 1445/4885PIM3 1645/4885CHEK1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.